Abstract: The present invention provides methods of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators, methods of preparing intermediates of pyrimidine cyclohexyl glucocorticoid receptor modulators, and pyridinium compounds.

Abstract: The present invention provides methods of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators, methods of preparing intermediates of pyrimidine cyclohexyl glucocorticoid receptor modulators, and thioether compounds.

Abstract: The present invention provides methods of preparing intermediates of heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: Provided herein is a method and apparatus for a starting head for a continuous casting mold, and more particularly, to a starting head configured to clinch a casting for drawing the casting from a continuous casting mold in a manner that reduces stresses within the casting decreasing the likelihood of stress cracks forming in the casting. An example starting head for a continuous casting mold includes: a body; a top surface of the body; two or more recesses defined within the top surface, where each recess extends from a first end to a second end, where the first end of a respective recess is closer to a center of the top surface than the second end of the respective recess, and where a depth of the first end of the respective recess relative to the top surface is less than a depth of the second end of the respective recess relative to the top surface; and a clinch point defined by the second end of the respective recess.

Abstract: The present invention provides methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators, and compositions having low impurity levels.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: Provided herein is a system, apparatus, and method for venting a direct chill casting mold by venting excess casting gas and retaining oxide from atop a casting during the direct chill casting process. Methods of venting casting gas from a direct chill casting mold include: supplying the direct chill casting mold with molten metal through a transition plate; supplying a casting gas through a casting surface of the direct chill casting mold; venting the casting gas from a gas pocket in the transition plate, wherein venting the casting gas from the gas pocket in the transition plate is performed in response to a pressure of the casting gas in the gas pocket reaching a predetermined pressure.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: Provided herein is a method and apparatus for a starting head for a continuous casting mold, and more particularly, to a starting head configured to clinch a casting for drawing the casting from a continuous casting mold in a manner that reduces stresses within the casting decreasing the likelihood of stress cracks forming in the casting. An example starting head for a continuous casting mold includes: a body; a top surface of the body; two or more recesses defined within the top surface, where each recess extends from a first end to a second end, where the first end of a respective recess is closer to a center of the top surface than the second end of the respective recess, and where a depth of the first end of the respective recess relative to the top surface is less than a depth of the second end of the respective recess relative to the top surface; and a clinch point defined by the second end of the respective recess.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: Provided herein is a system, apparatus, and method for venting a direct chill casting mold by venting excess casting gas and retaining oxide from atop a casting during the direct chill casting process. Methods of venting casting gas from a direct chill casting mold include: supplying the direct chill casting mold with molten metal through a transition plate; supplying a casting gas through a casting surface of the direct chill casting mold; venting the casting gas from a gas pocket in the transition plate, wherein venting the casting gas from the gas pocket in the transition plate is performed in response to a pressure of the casting gas in the gas pocket reaching a predetermined pressure.

Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: Clean condensate production may be produced from humidity in unfiltered air for an extended period of time using a membrane microgravity air conditioner which comprises an air box, comprising an inlet air flow path from a side face through an open top, and a filtering system disposed within the air box. The filtering system comprises one or more trash screens disposed in the inlet air flow path, one or more latent heat exchangers (LHX) disposed in the inlet air flow path, one or more particulate filters disposed in the inlet air flow path intermediate the trash screen and the LHX, one or more thermal control system (TCS) medium temperature loops, and one or more sensible heat exchangers (SHX) disposed in the inlet air flow path intermediate the particulate filter and the LHX.

Abstract: Clean condensate production may be produced from humidity in unfiltered air for an extended period of time using a membrane microgravity air conditioner which comprises an air box, comprising an inlet air flow path from a side face through an open top, and a filtering system disposed within the air box. The filtering system comprises one or more trash screens disposed in the inlet air flow path, one or more latent heat exchangers (LHX) disposed in the inlet air flow path, one or more particulate filters disposed in the inlet air flow path intermediate the trash screen and the LHX, one or more thermal control system (TCS) medium temperature loops, and one or more sensible heat exchangers (SHX) disposed in the inlet air flow path intermediate the particulate filter and the LHX.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.

Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1 and R2 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

Abstract: A method of managing an asynchronous messaging queue with a client computer in an asynchronous messaging system, where the client computer is programmed to store an manage the asynchronous messaging queue, includes receiving a reactive message in the asynchronous messaging queue, the reactive message including an identification of a previously initiated message and an action to be performed on the previously initiated message; and upon determining that the previously initiated message has already been received in the asynchronous messaging queue, performing the action on the previously initiated message with the client computer.